FDA approves Nplate® (Romiplostim) for use in pediatric patients with ITP
Amgen announced the FDA has approved the sBLA for Nplate® (romiplostim) for treatment of pediatric patients one year of age and older with immune thrombocytopenia for at least six months who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. December 14, 2018